Wilms tumor: An update

Advances in Anatomic Pathology

Volumn 21, Issue 3, 2014, Pages 166-173

  Al Hussain, Turki ^a   Ali, Afshan ^a   Akhtar, Mohammed ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

kidney; mutations; nephroblastoma; nephrogenic; syndromes; Wilms tumor

Indexed keywords

BETA CATENIN; CTNNB1 PROTEIN; PROTEIN P53; UNCLASSIFIED DRUG; WT1 PROTEIN;

ANAPLASTIC CARCINOMA; BECKWITH WIEDEMANN SYNDROME; BLASTEMA; CANCER ADJUVANT THERAPY; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL PROLIFERATION; CHROMOSOME 16Q; CHROMOSOME 1P; DENYS DRASH SYNDROME; DOWN REGULATION; EMBRYO DEVELOPMENT; GENE; GENE LOCUS; GENE MUTATION; GENETIC DISORDER; GLOMERULAR STRUCTURE; HETEROZYGOSITY LOSS; HISTOPATHOLOGY; HUMAN; KIDNEY CAPSULE; KIDNEY COLLECTING TUBULE; LOSS OF FUNCTION MUTATION; MALIGNANT TRANSFORMATION; MESODERM; METHYLATION; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMATIC MUTATION; UROGENITAL TRACT MALFORMATION; WAGR SYNDROME; WNT SIGNALING PATHWAY; WTX GENE; GENETICS; KIDNEY NEOPLASMS; PATHOLOGY; TUMOR SUPPRESSOR GENE; WILMS TUMOR;

GENES, WILMS TUMOR; HUMANS; KIDNEY NEOPLASMS; WILMS TUMOR;

EID: 84898403764     PISSN: 10724109     EISSN: 15334031     Source Type: Journal    
DOI: 10.1097/PAP.0000000000000017     Document Type: Review

References (68)

1. Breslow N, Olshan A, Beckwith JB, et al. Epidemiology of Wilms Tumor. Med Pediatr Oncol. 1993;21:172-181.
2. Dome JS, Huff V. Wilms tumor overview. In: Pagon RA, Adam MP, Bird TD, et al, eds. GeneReviewst [Internet]. Seattle, WA: University of Washington; 2003. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1294/.
3. Vujanic GM. Renal tumours of childhood: an overview. Diagn Histopathol. 2009;15:501-509.
4. Beckwith JB, Palmer NF. Histopathology and prognosis of Wilms tumor. Results from the First National Wilms' Tumor Study. Cancer Met Rev. 1978;41:1937-1948.
5. Weirich A, Leuschner I, Harms D, et al. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH. Ann Oncol. 2001;12:311-319.
6. Murphy WM, Grignon DJ, Perlman EJ. Kidney tumors in children. In: Murphy WM, Grignon DJ, Perlman EJ, eds. Tumors of the kidney, bladder, and urinary structures. Atlas of tumor pathology, 4th Series, Fascicle 1. Washington, DC: Armed Forces Institute of Pathology; 2004:57-64.
7. Eble JN, Sauter G, Epstein JI, et al. Tumours of the Urinary System and Male Genital Organs. Lyon: IARC; 2004.
8. Verschuur AC, Vujanic GM, Van Tinteren H, et al. Stromal and epithelial predominant Wilms tumours have an excellent outcome: the SIOP 93 01 experience. Pediatr Blood Cancer. 2010;55:233-238.
9. Beckwith JB, Zuppan CE, Browning NG, et al. Histological analysis of aggressiveness and responsiveness in Wilms' tumor. Med Pediatr Oncol. 1996;27:422-428.
10. Sultan I, Ajlouni F, Al-Jumaily U, et al. Distinct features of teratoid Wilms tumor. J Pediatr Surg. 2010;45:e13-e19.
11. Pollono D, Drut R, Tomarchio S, et al. Fetal rhabdomyomatous nephroblastoma: report of 14 cases confirming chemotherapy resistance. J Pediatr Hematol Oncol. 2003;25:640-643.
12. Dome JS, Cotton CA, Perlman EJ, et al. Treatment of anaplastic histology Wilms' tumor: results from the fifth National Wilms' Tumor Study. J Clin Oncol. 2006;24:2352-2358.
13. Faria P, Beckwith JB, Mishra K, et al. Focal versus diffuse anaplasia in Wilms tumor-new definitions with prognostic significance: a report from the National Wilms Tumor Study Group. Am J Surg Pathol. 1996;20:909-920.
14. Zuppan CW, Beckwith JB, Luckey DW. Anaplasia in unilateral Wilms tumor: a report from the National Wilms' Tumor Study Pathology Center. Hum Pathol. 1988;19:1199-1209.
15. Beckwith JB, Breslow NE, Faria P, et al. Treatment of children with stages II to IV anaplastic Wilms' tumor: a report from the National Wilms' Tumor Study Group. J Clin Oncol. 1994;12: 2126-2131.
16. Bosnib SM. Non neoplastic disease of the kidney. In: Bostwick DC, Cheng L, eds. Urologic Surgical Pathology. 2nd ed. Philadelphia, PA: MOSBY Elesvier; 2008:1-75.
17. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor: developmental and clinical considerations. Am J Med Genet. 1998;79:268-273.
18. Pritchard-Jones K, Gordan M, Vujani GM. Recent developments in the molecular pathology of paediatric renal tumors. Open Pathol J. 2010;4:32-39.
19. Zin RM, Murch A, Carles A. Pathology, genetics and cytogenetics of Wilms' tumour. Pathology. 2011;43:302-312.
20. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis, and the pathogenesis of Wilms' Tumor. Pediatr Pathol. 1990;10:1-36.
21. Vicens J, Iotti A, Lombardi MG, et al. Diffuse hyperplastic perilobar nephroblastomatosis. Pediatr Dev Pathol. 2009;12: 237-238.
22. Perlman EJ, Faria P, Soares A, et al. Hyperplastic perilobar nephroblastomatosis: long-term survival of 52 patients. Pediatr Blood Cancer. 2006;46:203-221.
23. Hennigar RA, O'Shea PA, Grattan-Smith JD. Features of nephrogenic rests and nephroblastomatosis. Adv Anat Pathol. 2001;8:276-289.
24. Argani P, Collins MH. Anaplastic nephrogenic rest. Am J Surg Pathol. 2006;30:1339-1341.
25. Vuononvirta R, Sebire NJ, Dallosso AR, et al. Perilobar nephrogenic rests are nonobligate molecular genetic precursor lesions of insulin-like growth factor-II-associated Wilms tumors. Clin Cancer Res. 2008;23:7635-7644.
26. Koziell A, Charmandari E, Hindmarsh PC, et al. Frasier syndrome, part of the Denys Drash continuum or simply a WT1 gene associated disorder of intersex and nephropathy? Clin Endocrinol (Oxf). 2000;52:519-524.
27. Kreidberg JA, Sariola H, Loring JM, et al. WT-1 is required for early kidney development. Cell. 1993;74:679-691.
28. Christopher R, Burrow CR. Regulatory molecules in kidney development. Pediatr Nephrol. 2000;14:240-253.
29. Hohenstein P, Hastie ND. The many facets of the Wilms' tumour gene, WT1. Hum Mol Genet. 2006;15:196-201.
30. Mrowka C, Schedl A. Wilms' tumor suppressor gene WT1: from structure to renal pathophysiologic features. J Am Soc Nephrol. 2000;11:S106-S115.
31. Segers H, Kersseboom R, Alders M, et al. Frequency of WT1 and 11p15 constitutional aberrations and phenotypic correlation in childhood Wilms tumour patients. Eur J Cancer. 2012;48:3249-3256.
32. Scott RH, Anne Murray A, Baskcomb L, et al. Stratification of Wilms tumor by genetic and epigenetic analysis. Oncotarget. 2012;3:327-335.
33. Satoh Y, Nakadate H, Nakagawachi T, et al. Genetic and epigenetic alterations on the short arm of chromosome 11 are involved in a majority of sporadic Wilms' tumours. Br J Cancer. 2006;95:541-547.
34. Fukuzawa R, Anaka MR, Heathcott RW, et al. Wilms tumour histology determined by distinct types of precursor lesions and not epigenetic changes. J Pathol. 2008;215:377-387.
35. Haruta M, Arai Y, Watanabe N, et al. Different incidences of epigenetic but not genetic abnormalities between Wilms tumors in Japanese and Caucasian children. Cancer Sci. 2012;103:1129-1135.
36. Fukuzawa R, Reeve AE. Molecular pathology and epidemiology of nephrogenic rests and Wilms tumors. J Pediatr Hematol Oncol. 2007;29:589-594.
37. Jenkins ZA, van Kogelenberg M, Morgan T, et al. Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009;41:95-100.
38. Fukuzawa R, Holman SK, Chow CW, et al. WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet. 2010;47:791-794.
39. Wegert J, Wittmann S, Leuschner I, et al. WTX inactivation is a frequent, but late event in Wilms tumors without apparent clinical impact. Chromosomes Cancer. 2009;48:1102-1111.
40. Perotti D, Gamba B, Sardella M, et al. Functional inactivation of the WTX gene is not a frequent event in Wilms' tumors. Oncogene. 2008;27:4625-4632.
41. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes Dev. 2012;26:1268-1286.
42. Bardeesy N, Falkoff D, Petruzzi MJ, et al. Anaplastic Wilms' tumour, a subtype displaying poor prognosis, harbours p53 gene mutations. Nat Genet. 1994;7:91-97.
43. Jadali F, Sayadpour D, Rakhshan M, et al. Immunohistochemical detection of p53 protein expression as a prognostic factor in Wilms tumor. Iran J Kidney Dis. 2011;5:149-153.
44. Grill C, SunItsch S, Hatz M, et al. Activation of beta-catenin is a late event in the pathogenesis of nephroblastomas and rarely correlated with genetic changes of the APC gene. Pathology. 2011;43:702-706.
45. Maiti S, Alam R, Amos CI, et al. Frequent association of betacatenin and WT1 mutations in Wilms tumors. Cancer Res. 2000;60:6288-6292.
46. Koesters R, Ridder R, Kopp-Schneider A, et al. Mutational activation of the beta-catenin proto-oncogene is a common event in the development of Wilms' tumors. Cancer Res. 1999;59:3880-3882.
47. Li CM, Kim CE, Margolin AA, et al. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1- mutant Wilms' tumors. Am J Pathol. 2004;65:1943-1953.
48. Spreafico F, Gamba B, Mariani L, et al. Loss of heterozygosity. Analysis at different chromosome regions in Wilms tumor confirms 1p allelic Loss as a marker of worse prognosis: a study from the Italian Association of Pediatric Hematology and Oncology. J Urol. 2013;189:260-267.
49. Grundy PE, Breslow NE, Li S, et al. Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol. 2005;23: 7312-7321.
50. Schaub R, Burger A, Bausch D, et al. Array comparative genomic hybridization reveals unbalanced gain of the MYCN region in Wilms tumors. Cancer Genet Cytogenet. 2007;72:61-65.
51. Bhatnagar S. Management of Wilms' tumor: NWTS vs. SIOP. J Indian Assoc Pediatr Surg. 2009;14:6-14.
52. Ahmed HU, Arya M, Tsiouris A, et al. An update on the management of Wilms' tumour. Eur J Surg Oncol. 2007;33: 824-831.
53. Vujanic GM, Sandstedt B. The pathology of Wilms' tumour (nephroblastoma): the International Society of Paediatric Oncology approach. J Clin Pathol. 2010;63:102-109.
54. Kusuma V, Gowda VKS, Geethamani Saini ML. Adult Wilms' tumour: a case report with review of literature. Diagn Pathol. 2006;1:46.
55. Terenziani M, Spreafico F, Collini P, et al. Adult Wilms' tumor: a monoinstitutional experience and a review of the literature. Cancer. 2004;101:289-293.
56. Ali AN, Diaz R, Shu HK, et al. A Surveillance, Epidemiology and End Results (SEER) Program comparison of adult and pediatric Wilms' tumor. Cancer. 2012;118: 2541-2551.
57. Karlsson J, Holmquist Mengelbier L, Elfving P, et al. Highresolution genomic profiling of an adult Wilms' tumor: evidence for a pathogenesis distinct from corresponding pediatric tumors. Virchows Arch. 2011;459:547-553.
58. Krishnan J, Pietras J, Nachmann M, et al. Adult Wilms' tumor with a unique presentation of high-grade fever, photophobia, and headache. Rev Urol. 2012;14:31-34.
59. Kilton L, Matthews MJ, Cohen MH. Adult Wilms tumor: a report of prolonged survival and review of literature. J Urol. 1980;124:1-5.
60. Adolphs HD, Knopfle G, Vogel J, et al. Wilms' tumor in the adolescent and adult. Eur Urol. 1983;9:281-287.
61. Jimenez RE, Folpe AL, Lapham RL, et al. Primary Ewing's sarcoma/primitive neuroectodermal tumor of the kidney: a clinicopathologic and immunohistochemical analysis of 11 cases. Am J Surg Pathol. 2002;26:320-327.
62. Argani P, Faria PA, Epstein JI, et al. Primary renal synovial sarcoma: molecular and morphologic delineation of an entity previously included among embryonal sarcomas of the kidney. Am J Surg Pathol. 2000;24:1087-1096.
63. Deshpande AV, Gawali JS, Sanghani HH, et al. Extrarenal Wilm's tumour-A rare entity. Pediatr Surg Int. 2002;18:543-544.
64. Yamamoto T, Nishizawa S, Ogiso Y. Paratesticular extrarenal Wilms' tumor. Int J Urol. 2012;19:490-491.
65. Rojas Y, Slater BJ, Braverman RM, et al. Extrarenal Wilms tumor: a case report and review of the literature. J Pediatr Surg. 2013;48:E33-E35.
66. Andrews PE, Kelalis PP, Haase GM. Extrarenal Wilms' tumor: results of the National Wilms' Tumor Study. J Pediatr Surg. 1992;27:1181-1184.
67. Jia HM, Zhang KR, Shu H, et al. Presacral extrarenal Wilms tumor in a child. Urology. 2009;74:308-310.
68. Aterman K. Extrarenal nephroblastomas. J Cancer Res Clin Oncol. 1989;115:409-417.